Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer

International Journal of Molecular Sciences

Volumn 13, Issue 8, 2012, Pages 9627-9641

  Xia, Jun ^a   Li, Youjian ^b   Yang, Qingling ^a   Mei, Chuanzhong ^a   Chen, Zhiwen ^a   Bao, Bin ^c   Ahmad, Aamir ^c   Miele, Lucio ^d   Sarkar, Fazlul H ^c   Wang, Zhiwei ^a,e  

^a BENGBU MEDICAL COLLEGE   (China)

^b TAIXING PEOPLE'S HOSPITAL   (China)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Arsenic trioxide; Breast cancer; Cell growth; NF B; Notch

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; MESSENGER RNA; ORGANOARSENIC DERIVATIVE; OXIDE; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE INACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; NF-KAPPA B; OXIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84865004392     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13089627     Document Type: Article

References (49)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2012, 62, 10-29.
2. Chlebowski, R.T.; Anderson, G.L. Changing concepts: Menopausal hormone therapy and breast cancer. J. Natl. Cancer Inst. 2012, 104, 517-527.
3. Reedijk, M. Notch signaling and breast cancer. Adv. Exp. Med. Biol. 2012, 727, 241-257.
4. Guo, S.; Liu, M.; Gonzalez-Perez, R.R. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta 2011, 1815, 197-213.
5. Harrison, H.; Farnie, G.; Brennan, K.R.; Clarke R.B. Breast cancer stem cells: something out of notching? Cancer Res. 2010, 70, 8973-8976.
6. Rizzo, P.; Osipo, C.; Pannuti, A.; Golde, T.; Osborne, B.; Miele, L. Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer. Adv. Enzym. Regul. 2009, 49, 134-141.
7. Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11, 338-351.
8. Han, J.; Hendzel, M.J.; Allalunis-Turner, J. Notch signaling as a therapeutic target for breast cancer treatment? Breast Cancer Res. 2011, 13, 210.
9. Dickson, B.C.; Mulligan, A.M.; Zhang, H.; Lockwood, G.; O'Malley, F.P.; Egan, S.E.; Reedijk, M. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod. Pathol. 2007, 20, 685-693.
10. Reedijk, M.; Odorcic, S.; Chang, L.; Zhang, H.; Miller, N.; McCready, D.R.; Lockwood, G.; Egan, S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65, 8530-8537.
11. Reedijk, M.; Pinnaduwage, D.; Dickson, B.C.; Mulligan, A.M.; Zhang, H.; Bull, S.B.; O'Malley, F.P.; Egan, S.E.; Andrulis, I.L. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res. Treat 2008, 111, 439-448.
12. Speiser, J.; Foreman, K.; Drinka, E.; Godellas, C.; Perez, C.; Salhadar, A.; Ersahin, C.; Rajan, P. Notch-1 and notch-4 biomarker expression in triple-negative breast cancer. Int. J. Surg. Pathol. 2012, 20, 137-143.
13. Yao, K.; Rizzo, P.; Rajan, P.; Albain, K.; Rychlik, K.; Shah, S.; Miele, L. Notch-1 and notch-4 receptors as prognostic markers in breast cancer. Int. J. Surg. Pathol. 2011, 19, 607-613.
14. Wang, Z.; Li, Y.; Ahmad, A.; Azmi, A.S.; Banerjee, S.; Kong, D.; Sarkar, F.H. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 2010, 1806, 258-267.
15. Baj, G.; Arnulfo, A.; Deaglio, S.; Mallone, R.; Vigone, A.; de Cesaris, M.G.; Surico, N.; Ferrero, E. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects. Breast Cancer Res. Treat 2002, 73, 61-73.
16. Chow, S.K.; Chan, J.Y.; Fung, K.P. Suppression of cell proliferation and regulation of estrogen receptor α signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells. J. Endocrinol. 2004, 182, 325-337.
17. Chow, S.K.; Chan, J.Y.; Fung, K.P. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J. Cell Biochem. 2004, 93, 173-187.
18. Lengfelder, E.; Hofmann, W.K.; Nowak, D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012, 26, 433-442.
19. Emadi, A.; Gore, S.D. Arsenic trioxide-An old drug rediscovered. Blood Rev. 2010, 24, 191-199.
20. Chen, G.C.; Guan, L.S.; Hu, W.L.; Wang, Z.Y. Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Res. 2002, 22, 633-638.
21. Wang, X.; Gao, P.; Long, M.; Lin, F.; Wei, J.X.; Ren, J.H.; Yan, L.; He, T.; Han, Y.; Zhang, H.Z. Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med. Oncol. 2011, 28, 1225-1254.
22. Osipo, C.; Golde, T.E.; Osborne, B.A.; Miele, L.A. Off the beaten pathway: The complex cross talk between Notch and NF-κB. Lab. Invest. 2008, 88, 11-17.
23. Ferreira, A.C.; Suriano, G.; Mendes, N.; Gomes, B.; Wen, X.; Carneiro, F.; Seruca, R.; Machado, J.C. E-cadherin impairment increases cell survival through Notch-dependent upregulation of Bcl-2. Hum. Mol. Genet. 2012, 21, 334-343.
24. Clementz, A.G.; Rogowski, A.; Pandya, K.; Miele, L.; Osipo, C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: Novel therapeutic implications. Breast Cancer Res. 2011, 13, R63.
25. Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A.G.; Hao, L.; Golde, T.E.; Miele, L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 2008, 27, 5019-5032.
26. Zang, S.; Chen, F.; Dai, J.; Guo, D.; Tse, W.; Qu, X.; Ma, D.; Ji, C. RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol. Rep. 2010, 23, 893-899.
27. Zhang, J.; Wang, B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol. Oncol. 2006, 103, 199-206.
28. Rizzo, P.; Miao, H.; D'Souza, G.; Osipo, C.; Song, L.L.; Yun, J.; Zhao, H.; Mascarenhas, J.; Wyatt, D.; Antico, G., et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008, 68, 5226-5235.
29. Korkaya, H.; Wicha, M.S. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin. Cancer Res. 2009, 15, 1845-1847.
30. Malhotra, G.K.; Zhao, X.; Band, H.; Band, V. Shared signaling pathways in normal and breast cancer stem cells. J. Carcinog. 2011, 10, 38.
31. Kondratyev, M.; Kreso, A.; Hallett, R.M.; Girgis-Gabardo, A.; Barcelon, M.E.; Ilieva, D.; Ware, C.; Majumder, P.K.; Hassell, J.A. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 2012, 31, 93-103.
32. McGowan, P.M.; Simedrea, C.; Ribot, E.J.; Foster, P.J.; Palmieri, D.; Steeg, P.S.; Allan, A.L.; Chambers, A.F. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol. Cancer Res. 2011, 9, 834-844.
33. Grudzien, P.; Lo, S.; Albain, K.S.; Robinson, P.; Rajan, P.; Strack, P.R.; Golde, T.E.; Miele, L.; Foreman, K.E. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010, 30, 3853-3867.
34. Efferson, C.L.; Winkelmann, C.T.; Ware, C.; Sullivan, T.; Giampaoli, S.; Tammam, J.; Patel, S.; Mestiti, G.; Reilly, J.F.; Gibson, R.E., et al. Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 2010, 70, 2476-2484.
35. Imbimbo, B.P. Therapeutic potential of γ-secretase inhibitors and modulators. Curr. Top Med. Chem. 2008, 8, 54-61.
36. de Thé, H.; Chen, Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat. Rev. Cancer 2010, 10, 775-783.
37. Diepart, C.; Karroum, O.; Magat, J.; Feron, O.; Verrax, J.; Calderon, P.B.; Grégoire, V.; Leveque, P.; Stockis, J.; Dauguet, N., et al. Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors. Cancer Res. 2012, 72, 482-490.
38. Pettersson, H.M.; Pietras, A.; Munksgaard Persson, M.; Persson, M.; Karlsson, J.; Johansson, L.; Shoshan, M.C.; Pahlman, S. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol. Cancer Ther. 2009, 8, 160-170.
39. Chiu, H.W.; Chen, Y.A.; Ho, S.Y.; Wang, Y.J. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One 2012, 7, e31579.
40. Uslu, R.; Sanli, U.A.; Sezgin, C.; Karabulut, B.; Terzioglu, E.; Omay, S.B.; Goker, E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 2000, 6, 4957-4964.
41. Liu, Y.; Zhang, W.; Zhang, X.; Qi, Y.; Huang, D.; Zhang, Y. Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway. Exp. Biol. Med. (Maywood) 2011, 236, 592-597.
42. Tingting, R.; Wei, G.; Changliang, P.; Xinchang, L.; Yi, Y. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. Cancer Biol. Ther. 2010, 10, 251-257.
43. Park, M.J.; Lee, J.Y.; Kwak, H.J.; Park, C.M.; Lee, H.C.; Woo, S.H.; Jin, H.O.; Han, C.J.; An, S.; Lee, S.H., et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J. Cell Biochem. 2005, 95, 955-969.
44. Zhen, Y.; Zhao, S.; Li, Q.; Li, Y.; Kawamoto, K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010, 292, 64-72.
45. Wang, Z.; Kong, D.; Banerjee, S.; Li, Y.; Adsay, N.V.; Abbruzzese, J.; Sarkar, F.H. Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res. 2007, 67, 11377-11385.
46. Wang, Z.; Zhang, Y.; Li, Y.; Banerjee, S.; Liao, J.; Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5, 483-493.
47. Wang, Z.; Azmi, A.S.; Ahmad, A.; Benerjee, S.; Wang, S.; Sarkar, F.H.; Mohammad, R.M. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: Involvement of Notch-1 signaling pathway. Cancer Res. 2009, 69, 2757-2765.
48. Weijzen, S.; Rizzo, P.; Braid, M.; Vaishnav, R.; Jonkheer, S.M.; Zlobin, A.; Osborne, B.A.; Gottipati, S.; Aster, J.C.; Hann, W.C., et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8, 979-986.
49. Wang, Z.; Banerjee, S.; Li, Y.; Rahman, K.M.; Zhang, Y.; Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66, 2778-2784.